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The main objective of this study was to test whether pre-treatment coronary artery 
calcium (CAC) was associated with the cumulative incidence of acute coronary 
events (ACE) among breast cancer (BC) patients treated with postoperative 
radiotherapy (RT).
Material and methods 
The study population consisted of 939 consecutive female BC patients treated 
with RT. The association between CAC and ACE was tested using Cox-proportional 
hazard models. Known risk factors for ACE and the mean heart dose (MHD), 
collected from three-dimensional computed tomography planning data, were 
tested for confounding.
Results
CAC scores varied from 0 to 2,859 (mean 27.3). The 9-year cumulative incidence 
of ACE was 3.2%, this was significantly associated with the pre-treatment CAC 
score. After correction for confounders, age, history of ischemic heart disease, 
diabetes, Body Mass Index ≥30, MHD, hypercholesterolemia and hypertension, 
the hazard ratio for ACE for the low and the combined intermediate and high 
CAC score category were 1.42 (95%CI: 0.49-4.17; p = 0.519) and 4.95 (95%CI: 
1.69-14.53; p = 0.004) respectively, compared to the CAC zero category.
Conclusions
High pre-treatment CAC is associated with ACE in BC patients treated with 
postoperative RT, even after correction for confounding factors such as MHD.












Survival rates of breast cancer (BC) patients have gradually improved.1 This 
improvement in survival is partly due to intensified treatment, such as radiotherapy 
(RT) and the use of more effective systemic agents.2,3 Due to these higher survival 
rates, more BC patients are at risk of developing treatment-related side effects, 
such as radiation-induced cardiac toxicity. Although the introduction of more 
advanced radiation techniques has led to a substantial decrease in the radiation 
dose to the heart, in some cases the heart still receives a considerable radiation 
dose, which may contribute to the development of cardiac toxicity.4 Recent studies 
showed that the risk of acute coronary events (ACE) in the first 9 years of follow-up 
increases by ~16% per Gray (Gy) of mean heart dose (MHD).5,6 These studies 
also indicated that the absolute excess risk induced by RT strongly depends on 
baseline cardiovascular risk factors. Therefore, it becomes increasingly important 
for radiation oncologists to identify which baseline factors are important for BC 
patients. This will facilitate calculation of the absolute excess risk of radiation-
induced ACE in individual patients. This information can be used to select BC 
patients for primary or secondary preventive measures.
The amount of coronary artery calcium (CAC), as determined from Computed 
tomography (CT), is a well-established and reliable early predictor of ACE in 
the general population.7,8,9 To establish the amount of CAC, deposits of calcium 
in the coronary arteries are quantified according to the Agatston score (AS).10 
Higher CAC scores correspond to a higher risk of ACE.7,8,9,10 In general, CAC is 
measured using diagnostic electrocardiogram (ECG) triggered CT scans. However, 
CAC scores can be obtained using non-triggered CT scans as well.11,12,13,14,15 For 
RT treatment planning, BC patients generally undergo a non-triggered CT scan, 
which can be used to determine the baseline CAC value.
The main objective of this study was to test the hypothesis that pre-treatment 
CAC scores, based on non-triggered planning CT scans, are associated 




The population of this retrospective study was composed of a consecutive series 
of female BC patients who were treated between January 2005 and December 
2008 at the University Medical Center, Groningen, The Netherlands. These 
patients were treated for invasive BC stages I-III or ductal carcinoma in situ (DCIS). 
Treatment consisted of curative breast-conserving surgery followed by RT. A dose 
of 50.4 Gy was prescribed for the whole breast in 28 fractions, with a simultaneous 
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integrated boost dose of 14 or 16.8 Gy in the same 28 fractions, depending on 
pathologic risk factors.6 Patients were only included if their treatment planning 
CT scans made prior to RT were available. Patients were excluded if they had 
a medical history of cancer (except for non-melanoma skin cancer) or had 
received prior RT or prior chemotherapy treatment. Patients with a history of 
cardiac disease were not excluded due to the fact that our aim was to develop 
an association model applicable to the general BC population. In contrast to 
a prediction model, an association model only describes the relationship between 
one predictor (i.e. CAC score) and the outcome (i.e. ACE) after correction for 
confounding factors. Patient characteristics, follow up data, information on 
cardiovascular risk factors and ACE were retrospectively extracted from patient 
hospital records. Missing data were supplemented with information derived from 
the general practitioner records after obtaining written informed consent from 
the surviving patients. Information about deceased patients was provided by 
the general practitioners, as in accordance with Dutch regulations. The following 
baseline patient characteristics were included in the analysis: age, history of 
ischemic heart disease (International Classification of Diseases, 10th Revision 
[ICD-10] codes I20-I25), other heart diseases (ICD-10 codes I30-I52), diabetes 
of any type (ICD-10 E10-E14), chronic obstructive pulmonary disease (COPD) 
of any type (ICD-10 J44), smoking status, body mass index (BMI), hypertension 
(ICD-10 I10-I15), hypercholesterolemia (ICD-10 E78.0) and the MHD. Ischemic 
heart disease, other heart disease, diabetes and COPD were considered when 
the diagnosis was stated in patients’ medical charts. Smoking status was stratified 
into currently smoking or not smoking at baseline. BMI was stratified into two 
categories <30 and ≥30 kg/m2. Hypertension was considered when diagnosis was 
stated (systolic blood pressure ≥140 mmHg and/or when diastolic blood pressure 
≥90 mmHg) or when antihypertensive medication was used. Hypercholesterolemia 
was considered present if identified at clinical diagnosis or when statins were 
used (unless they were preventively used because of present cardiovascular 
risk factors such as diabetes). The MHD in Gray (Gy) was collected from three-
dimensional (3D) conformal RT treatment plans based on the individual planning 
CT scans. The primary endpoint was the occurrence of ACE defined as diagnosis 
of myocardial infarction (ICD-10 I21-I24), coronary revascularization or death 
from ischemic heart disease (ICD-10 I20-I25). The study design was approved by 
the medical ethics committee of the University Medical Center Groningen.
Data collection and procedures
The CT scans used in this study were non-triggered CT scans (SOMATOM 
Sensation Open, 40 slice, Siemens Medical Inc.) acquired for RT treatment 
planning. The scanning protocol for the planning CT scans was different from 











that used in a dedicated CAC scan procedure, mandating correction of the CAC 
scores. For the correction of the CAC scores, a thorax phantom with calibration 
inserts was scanned (QRM Thorax & QRM-CCI, QRM, Germany) according to both 
the diagnostic CAC protocol and the RT planning CT protocol (Supplementary 
material table 1). Rings of fat were placed around the phantom to represent 
patients of medium and large size.16 Thereafter, the different amounts of calcium 
per calcium insert were determined from the multiple CT scans and quantified 
with the Aquarius software (iNtuition edition, v4.4.11.412.8585, Tera Recon, 
Inc.) according to the AS. Settings for the Aquarius software can be found in 
the supplementary material table 2. The correction formula was obtained by 
plotting the CAC scores from the calcium inserts of the QRM phantom from 
the planning CT scan against that of the diagnostic scan (Supplementary material: 
table 3 and Figs. 1-4).
To establish the CAC scores of the BC patients, the calcified lesions were 
selected and labeled per coronary artery by hand by a single trained technician. 
Subsequently, the software calculated the total CAC score. For patients with 
planning CT scans on which CAC was difficult to assess, experienced researchers 
of the Radiology department were consulted. Although patients with coronary 
stents and/or surgical clips due to cardiac surgery are at higher risk of ACE, these 
patients had to be excluded because CAC measurements were not possible due to 
artifacts. The CAC scores of the BC cohort were transformed using the correlation 
formulas described above (Supplementary material table 3). The formulas were 
only used for patients with a CAC score higher than zero.
Statistics
To provide clinically relevant and easily applicable results, we first classified 
the CAC score into widely used clinical CAC score categories: CAC zero (0), low 
CAC (>0-<100), intermediate CAC (100-400) and high CAC (≥400).7,15,17,18,19,20 
However, due to limited number of events in the high CAC score category we 
combined the intermediate and high CAC into one variable to maintain sufficient 
statistical power.
The cumulative incidence of ACE was calculated from the date of the first RT 
treatment using the Kaplan Meier method. Patients were censored when receiving 
a new radiation treatment, at time of death or at the end of the follow-up period.
The association between the CAC score and the cumulative incidence of 
ACE was first tested with a univariable Cox-regression analysis. Thereafter, all 
cardiovascular risk factors and the MHD were examined as possible confounders 
in a multivariable Cox-regression association model with the CAC score category 
as the main determinant. This was done by iteratively adding these risk factors 
to the univariable Cox-regression analysis. The risk factor that caused the largest 
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change in the regression coefficients of the determinant (with a minimum of 10%) 
was selected as a confounder. This process was repeated with the remaining 
risk factors until the change in regression coefficients of the determinant was 




The consecutive BC cohort consisted of 1,032 eligible patients. Fifty-six patients 
were excluded because they had been scanned with a different CT scanner, 8 
because of missing CT data, 23 because of deviating CT scan protocol and 6 
patients were excluded because their coronary stents caused too many artifacts 
for reliable CAC scoring. Eventually, a total of 939 patients were included 
in the analysis (table 1). The mean age was 58.4 years (range: 26-84 years). 
The median follow-up was 7.5 years. The CAC scores were highly skewed and 
ranged from 0 to 2,859, with a mean CAC score of 27.3 and a median of 0. Most 
patients (78.9%) were in the CAC zero category, 14.5% in the low CAC category, 
5.2% of the patients were in the intermediate CAC category and 1.4% were in 
the high CAC category (Supplementary material table 4).
Association between CAC and ACE
In total, 29 out of 939 patients developed ACE during follow-up: 13 out of 
741 patients in the CAC zero category, 6 out of 136 patients in the low CAC 
category, 7 out of 49 patients in the intermediate CAC category and 3 out of 
13 patients in the high CAC category. Due to the limited number of events, we 
combined the intermediate with the high CAC category, to maintain sufficient 
statistical power. The 9-year cumulative incidence of ACE was 3.2% (figure 1). 
The cumulative incidence of ACE per CAC score category is shown in figure 2. 
The univariable Cox-regression analysis showed a significant association between 
the CAC score and the cumulative incidence of ACE (table 2). This is true for 
all CAC categories; the comparison of the low CAC versus CAC zero category 
(HR: 2.75; 95%CI: 1.03-7.32, p = 0.043) and for the comparison of the combined 
intermediate and high CAC versus CAC zero category (HR: 11.57; 95%CI: 5.00-
26.81, p < 0.001).
Multivariable analysis showed that age, history of ischemic heart disease, 
diabetes, BMI ≥30, MHD, hypercholesterolemia and hypertension were 
confounders for the association between CAC and the cumulative incidence of 
ACE. After correction for these confounders in the Cox-regression association 
model, the hazard ratios for the low and the combined intermediate and high 











Table 1. Patient characteristics at baseline.
Characteristic N %
Total 939 100
Age in years, mean (range) 58.4 (26-84)
History of (cardiac) comorbidity 









































BMI <30 852 90.7











Nx / unknown 36 3.8




Chemotherapy only 103 11.0
Endocrine therapy only 160 17.0






Abbreviations: ACE, acute coronary events; BMI, body mass index; MHD, mean heart dose; Gy, Gray.
* History of ischemic heart disease was defined when myocardial infarction, coronary revascularisation 
or angina was documented in the patient record.
§ COPD with any type of GOLD-class.
¶ Any type of diabetes.
CAC categories versus the CAC zero category were 1.42 (95%CI: 0.49-4.17, 
p = 0.52) and 4.95 (95%CI: 1.69-14.53, p = 0.004), respectively (table 2).
DISCUSSION
This study showed that a high CAC score (CAC ≥ 100) assessed with a non-
triggered planning CT scan is associated with ACE in a BC population treated 












































Time from start radiotherapy (years)









































































Time fro  start radiotherapy (years)
Log rank test .
CAC score 0  
Low CAC score
Intermediate + high CAC score
Number of patients at risk
Intermed + high CAC       62           59              57              56          52            49          44              27              13               4
Low CAC                          136            135            133            129           128            127            120             86        30              12
CAC zero                          741            736            728           718     703          688            668            499            279  73
Figure 1. Cumulative incidence with 95% confidence interval of acute coronary events in 
the entire breast cancer population.
Figure 2. Cumulative incidence of acute coronary events per coronary artery calcium (CAC) 
score category.
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Table 2. Cox-regression association model for the cumulative incidence of acute coronary 
events for the different coronary artery calcium (CAC) categories, compared to the CAC 
zero category. Age, history of ischemic heart disease, diabetes, BMI ≥30, mean heart dose, 
hypercholesterolemia and hypertension were identified as confounders for the association 
between CAC and the cumulative incidence of acute coronary events.
Description β Change of β HR 95% CI HR P
Not corrected
CAC zero (reference) 1
Low CAC 1.01 2.75 1.03-7.32 0.043
Intermediate + high CAC 2.45 11.57 5.00-26.81 < 0.001
Corrected for age
CAC zero (reference) 1
Low CAC 0.5 -50.50% 1.65 0.60-4.54 0.331
Intermediate + high CAC 1.51 -38.40% 4.55 1.72-12.04 0.002
Age 1.08 1.03-1.13 0.001
Corrected for age and history of ischemic heart disease
CAC zero (reference) 1
Low CAC 0.37 -26.00% 1.44 0.52-4.03 0.486
Intermediate + high CAC 1.27 -15.90% 3.57 1.32-9.69 0.012
Age 1.07 1.03-1.12 0.002
History of ischemic heart disease 3.52 1.40-8.86 0.007
Corrected for age, history of ischemic heart disease and diabetes
CAC zero (reference) 1
Low CAC 0.27 -27.00% 1.31 0.46-3.70 0.611
Intermediate + high CAC 1.39 9.40% 4.02 1.47-10.98 0.007
Age 1.07 1.20-1.12 0.005
History of ischemic heart disease 3.32 1.31-8.40 0.011
Diabetes 2.73 1.07-6.97 0.036
Corrected for age, history of ischemic heart disease, diabetes and BMI≥30
CAC zero (reference) 1
Low CAC 0.36 33.30% 1.44 0.51-4.09 0.494
Intermediate + high CAC 1.48 6.50% 4.39 1.60-12.09 0.004
Age 1.07 1.02-1.12 0.004
History of ischemic heart disease 3.3 1.32-8.28 0.011
Diabetes 2.6 1.02-6.66 0.046
BMI≥30 1.99 0.66-5.99 0.219












β Change of β HR 95% CI HR P
Corrected for age, history of ischemic heart disease, diabetes, BMI≥30 and mean  
heart dose
CAC zero (reference) 1
Low CAC 0.47 30.60% 1.59 0.55-4.63 0.393
Intermediate + high CAC 1.61 8.80% 4.99 1.69-14.77 0.004
Age 1.07 1.01-1.11 0.013
History of ischemic heart disease 3.66 1.45-9.21 0.006
Diabetes 2.88 1.10-7.49 0.031
BMI≥30 2.15 0.70-6.63 0.182
Mean heart dose 1.17 1.00-1.37 0.054
Corrected for age, history of ischemic heart disease, diabetes, BMI≥30, mean heart 
dose and hypercholesterolemia
CAC zero (reference) 1
Low CAC 0.39 -17.00% 1.48 0.50-4.36 0.476
Intermediate + high CAC 1.62 0.60% 5.03 1.69-15.01 0.004
Age 1.06 1.01-1.11 0.019
History of ischemic heart disease 3.25 1.24-8.54 0.017
Diabetes 2.69 1.01-7.14 0.047
BMI≥30 2.1 0.69-6.41 0.194
Mean heart dose 1.18 1.01-1.39 0.042
Hypercholesterolemia 1.51 0.63-3.63 0.357
Corrected for age, history of ischemic heart disease, diabetes, BMI≥30, mean heart 
dose, hypercholesterolemia and hypertension
CAC zero (reference) 1
Low CAC 0.35 -10.30% 1.42 0.49-4.17 0.519
Intermediate + high CAC 1.6 -1.20% 4.95 1.69-14.53 0.004
Age 1.05 1.01-1.11 0.028
History of ischemic heart disease 3.06 1.17-8.03 0.023
Diabetes 2.49 0.93-6.67 0.07
BMI≥30 1.86 0.60-5.80 0.283
Mean heart dose 1.18 1.00-1.39 0.05
Hypercholesterolemia 1.36 0.56-3.33 0.497
Hypertension 1.57 0.66-3.74 0.308
Abbreviations: β, regression coefficient; HR, hazard ratio; CI, confidence interval; CAC, coronary 
artery calcium; BMI, body mass index.
CAC score categories: Low CAC (CAC score >0-100), intermediate + high CAC (CAC score >100).
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with postoperative RT. This holds even after correction for confounding factors, 
such as MHD.
There are several studies on CAC scoring in BC patients. A recent study, 
investigating the reproducibility of automatic coronary artery calcium scoring in 
a BC population, found a baseline CAC score of zero in 76% of the BC patients.15 
These results are comparable to the 78,9% found in our study. In another much 
smaller study 53% of the BC patients had a CAC score of zero.19 This difference 
could be attributed to the study size.
Accelerated coronary atherosclerosis is considered one of the mechanisms of 
radiation induced cardiac toxicity and can lead to serious cardiac morbidity and 
mortality.21 Three studies have measured the amount of CAC in the years following 
RT treatment for BC. In two studies, no elevated CAC scores in BC patients were 
found 5 to 15.7 years after RT treatment, whereas 1 study did find an increase in 
CAC score depending on radiation dose to the heart.22,23,24 Of the studies that 
did not find a CAC score increase, one did not include baseline CAC scores and 
the other only included a relatively small number of patients, which makes it 
difficult to draw definitive conclusions from these two studies. In young Hodgkin’s 
lymphoma survivors (all under 55 years) elevated CAC scores have been found 
in the 5 to 35 years after RT.25,26,27 A study in the general population investigated 
CAC scores at baseline and after 10 years of follow-up.28 The results showed 
that the diagnosis of cancer and its treatments were significantly associated 
with the development of CAC, even after accounting for atherosclerotic risk 
factors. The results of these studies suggest that RT could be associated with 
increased CAC scores in the long term and therefore supports the hypothesis that 
accelerated atherosclerosis is one of the mechanisms contributing to radiotherapy 
induced cardiac events.
There are some studies concerning non-triggered CAC scores and 
the association with ACE, conducted in a general population and in lung cancer 
patients.29,14 Studies concerning the general population had a median follow-up 
time ranging from 7.0 to 11.6 years. Overall, higher CAC scores were significantly 
associated with cardiovascular events. Compared to the zero CAC score group, 
the HRs were 1.53 (95%CI: 1.02-2.29) for the group of patients with a CAC score 
of >0-100 and 4.02 (95%CI: 2.62-6.19) for the group with a CAC score of >100.
A possible limitation of this study was that during planning CT scan acquisition, 
patients were instructed to breathe normally and no ECG triggering was used. 
This causes motion of the cardiac structures and calcium spots on CT images, 
leading to an under- or overestimation of calcium. However, several studies 
showed that CAC scoring can also be adequately performed with non-triggered 
CT scans.11,12,13,14 A high level of agreement was found after investigating 
the correlations of CAC scores between non-triggered and triggered thoracic CT 
scans.12 Therefore, it should be emphasized that a CAC score of zero measured 











on a non-triggered CT scan does not necessarily imply that there are absolutely 
no calcifications, but still indicates a low risk of ACE.13,14 Yet, as shown in these 
studies a high CAC score is a reliable prognostic marker to identify high risk 
patients of ACE.13,14
In the current study, patients with coronary stents and/or clips that caused too 
many artifacts were excluded. These patients underwent cardiac interventions 
and can be considered as high risk patients of ACE, which could lead to an 
underestimation of the calcium scores in our population. As shown by recent 
studies the absolute risk of developing ACE is the highest in patients with 
cardiovascular risk factors and a higher radiation dose to the heart.5,6 Results of 
the current study show that patients with high baseline CAC scores are at higher 
risk to develop ACE. In this respect, information on baseline risks, including 
the CAC score combined with the dose distribution to the heart, is useful to 
identify patients that may benefit from more advanced radiation techniques to 
reduce the heart dose.30,31,32,33,34
In conclusion, high pre-treatment CAC score measured on non-triggered 
planning CT scans is significantly associated with the cumulative incidence of 
ACE among BC patients treated with postoperative RT even after correction for 
confounding. CAC can be used to identify patients that may benefit from primary 
and secondary preventive measures.
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Table 1. CT scan protocols
kV mA Slice (mm)
Increment 
(mm)
Planning CT scan protocol
2005 - September 2007 140 100 5 5
September 2007- 2008 140 100 3 3
Diagnostic CAC score CT scan protocol
120 200 3 3
Abbreviations: kV, kilovoltage; mA, mili ampere; CAC, coronary artery calcium.
Table 2. Aquarius options for calcium detection
Options Setting
Lay-Over (Hounsfield Units) 130 -1300
Isotropically interpolated volumes Yes
Noise rejection – connected pixels 2
Connectivity Diagonally and laterally
Table 3. Calibration factors and correlation formulas. (X=patient coronary artery calcium 
(CAC) score, Y=related diagnostic CAC score)
Planning scan protocol Patient size Correlation formula
5mm slices & increment Thin y=0.964x + 5.317
Thick y=1.094x – 0.791
3mm slices & increment Thin y=1.037x + 1.912




































Calcium scores thin phantom radiotherapy setting 
(5mm)











Mean age 56.3 64.3 69.4 73.5
<45 102 (97.1%) 3 (2.9%) 0 (0%) 0 (0%)
45-54 226 (93.8%) 13 (5.4%) 2 (0.8%) 0 (0%)
55-64 251 (80.2%) 49 (15.6%) 10 (3.2%) 3 (1.0%)
65-74 138 (61.0%) 58 (25.7%) 26 (11.5%) 4 (1.8%)
75-84 24 (44.4%) 13 (24.1%) 11 (20.4%) 6 (11.1%)
Total 741 (78.9%) 136 (14.5%) 49 (5.2%) 13 (1.4%)
Abbreviations: CAC, Coronary Artery Calcium.
Appendix Figure 1. The coronary artery calcium scores of the calcium inserts from the QRM 
phantom scanned with the diagnostic coronary artery calcium scanning protocol and 
radiotherapy planning scanning protocol. Used for the correlation formula: 5 millimetre 
slices and increment, thin patient.














































Calcium scores thick phantom radiotherapy setting 
(5mm)
Appendix Figure 2. The coronary artery calcium scores of the calcium inserts from the QRM 
phantom scanned with the diagnostic coronary artery calcium scanning protocol and 
radiotherapy planning scanning protocol. Used for the correlation formula: 5 millimetre 




































Calcium scores thin phantom radiotherapy setting 
(3mm) 
Appendix Figure 3. The coronary artery calcium scores of the calcium inserts from the QRM 
phantom scanned with the diagnostic coronary artery calcium scanning protocol and 
radiotherapy planning scanning protocol. Used for the correlation formula: 3 millimetre 
slices and increment, thin patient.














































Calcium scores thick phantom radiotheapy setting 
(3mm)
Appendix Figure 4. The coronary artery calcium scores of the calcium inserts from the QRM 
phantom scanned with the diagnostic coronary artery calcium scanning protocol and 
radiotherapy planning scanning protocol. Used for the correlation formula: 3 millimetre 
slices and increment, thick patient.
